You are here: Planet Chiropractic > News > Article Serving Chiropractors Worldwide


Planet Chiropractic News | School Rankings | Blog | Events | e-Mail | Classifieds | Audio/Video | Search
Chiropractic Jobs | Practices for Sale | Employment | Billing Services

Search:

Posted on: Wednesday, March 22, 2000
From Diabetes to Death - FDA Takes Diabetes Drug Off Market
planetc1.com-news email to the editor
Several sources are reporting today that the Diabetes drug Rezulin has been pulled from the market since it has been linked to at least 61 deaths.

The FDA requested on Tuesday that the drug be removed due to its risks of use and reported deaths associated with its use. At least 61 individuals have died from liver poisoning after being treated with the drug, according to reports.

The Los Angeles Times began running reports on the dangers of Rezulin some months ago and has several articles available on the L.A. Times website.

See our report from December 1999 which includes links to the L.A. Times reports.

More Rezulin Drug Deaths Despite Warning

Links: FDA Takes Rezulin Off Market, Citing Deaths

Diabetes drug withdrawn from the market Yahoo's Health News

L.A. Times: Diabetes Drug Rezulin Pulled Off the Market

Subscribe RSS: Add to Google Add to My Yahoo! RSS Feeds XML Feeds

E-mail newsletters

Fresh News Daily
Enter your email address:




Search:


Select Featured Articles
Running Girl
Chiropractic Los Angeles:
What it's like
Featured Article - Chiropractor Salaries
Assessing
Chiropractor Salaries
Featured Article
Pregnancy &
Chiropractic
Females & Bones
Estrogen, Hormones,
Osteoporosis and Bones

  Home | News | Blog | Events | e-Mail | Classifieds | Audio/Video | Search | About


Copyright © 2000 - 2008 Planet Chiropractic. All rights reserved. The content (including but not limited to text, photo,
multimedia information, etc) published on this site belongs to Planet Chiropractic (planetc1,LLC). Without written
authorization from planetc1,LLC, such content shall not be republished or used in any form.
Questions or Comments - Privacy Policy - Terms of Service